iProTide

Company Overview

Snapshot

Founded in January 2010, iProTide operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on research and development.

Business overview

iProTide is a Health Tech & Life Sciences company focused on enhancing protein-based drug discovery. The company's core technology involves chemical modifications within the backbone of proteins and amino acids to improve their stability, folding properties, activity, and specificity. iProTide initially targets peptides and proteins associated with obesity and diabetes, aiming to develop new treatments and potentially enable the re-use of peptides/proteins that previously failed clinical trials due to pharmacokinetic/pharmacodynamic, toxicity, or efficiency issues. The company operates in the Pharmaceuticals sector, serving the Life Sciences and Healthcare & Life Sciences markets globally.

Company Intelligence Q&A

What is iProTide's primary focus?

iProTide primarily focuses on enhancing protein-based drug discovery through innovations related to the physical, chemical, and biological properties of amino acids, with an initial emphasis on obesity and diabetes treatments.

What is the core technology behind iProTide's approach?

iProTide's technology is based on chemical modifications made within the backbone of proteins and amino acids without altering the side chain, aiming to create enhanced proteins with better stability, distinct folding properties, and improved activity and specificity.

Which therapeutic areas does iProTide initially target?

iProTide initially plans to focus on peptides and proteins associated with obesity and diabetes, addressing an unmet need for efficacious, stable, and specific protein/peptide therapeutics.

What problem does iProTide aim to solve in drug development?

iProTide aims to solve the problem of developing highly efficacious, stable, and specific protein/peptide drugs, and potentially enable the re-use of peptides/proteins that previously failed clinical trials due to issues like pharmacokinetics/pharmacodynamics, toxicity, and efficiency.

What is the current product stage of iProTide?

iProTide is currently in the Research & Development (R&D) product stage, working on its protein enhancement technology.